Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00003926
Other study ID # 1997LS053
Secondary ID UMN-MT-9713UMN-9
Status Terminated
Phase Phase 1
First received November 1, 1999
Last updated November 27, 2017
Start date November 1998
Est. completion date August 2003

Study information

Verified date November 2017
Source Masonic Cancer Center, University of Minnesota
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of high-dose chemotherapy.

PURPOSE: Phase I trial to study the effectiveness of amifostine in protecting from the side effects of peripheral stem cell transplantation in treating patients who have high-risk or relapsed solid tumors.


Description:

OBJECTIVES:

- Determine the dose-limiting toxicity of amifostine chemoprotection with peripheral blood stem cell transplantation plus chemotherapy in patients with high-risk or relapsed solid tumors or brain tumors.

- Determine response or time to disease progression in patients treated with this regimen.

OUTLINE: This is a dose-escalation study of amifostine. Patients are stratified according to age (1 to 18 vs 19 to 45 years).

All patients receive filgrastim (G-CSF) IV for 1 week. On day 6 of G-CSF administration, patients undergo peripheral blood stem cell (PBSC) harvest followed by chemotherapy.

Patients receive oral busulfan every 6 hours on days -8 to -6 followed by melphalan IV over 30 minutes on days -5 and -4 and thiotepa IV over 2 hours on days -3 and -2. Patients receive amifostine IV over 5 minutes beginning 30 minutes prior to melphalan and thiotepa administration on days -5 to -1. PBSC are reinfused on day 0.

Cohorts of 3-6 patients receive escalating doses of amifostine until the maximum tolerated dose is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients are followed on day 50; at 3, 6, and 9 months; and at 1, 2, and 3 years post PBSC transplantation.

PROJECTED ACCRUAL: A maximum of 60 patients (30 per stratum) will be accrued for this study within 3 years.


Recruitment information / eligibility

Status Terminated
Enrollment 13
Est. completion date August 2003
Est. primary completion date August 2002
Accepts healthy volunteers No
Gender All
Age group 1 Year to 45 Years
Eligibility Inclusion Criteria:

- Histologically confirmed high-risk or relapsed solid tumors or brain tumors, including:

- Metastatic or relapsed Ewing's sarcoma

- Metastatic or relapsed rhabdomyosarcoma

- Refractory Wilms' tumor

- Diffuse anaplastic Wilms' tumor

- Stage III or IV neuroblastoma

- Recurrent retinoblastoma

- Metastatic or relapsed germ cell tumors

- Metastatic or relapsed other soft tissue sarcomas

- Small cell ovarian sarcoma

- Metastatic or relapsed primitive neuroectodermal tumors of the bone

- Recurrent brain tumors

- Desmoplastic small round cell tumors

- Recurrent or metastatic chordomas

- Metastatic or relapsed hepatoblastoma

- Patients receive peripheral blood stem cell transplantation only if in complete remission or in very good partial remission with no disease progression

- Must have radiologic, nuclear image, or histologic verification of relapse

- Age 1 to 45

- Performance status:Karnofsky 70-100%

- Absolute neutrophil count greater than 1,000/mm^3

- Platelet count greater than 100,000/mm^3

- Hemoglobin count at least 10 g/dL

- Bilirubin less than 2 times upper limit of normal (ULN)

- SGOT or SGPT less than 2.5 times ULN

- Creatinine less than 2 times ULN

- Creatinine clearance greater than 70 mL/min

- Cardiac shortening fraction greater than 30%

- Cardiac ejection fraction greater than 45%

- At least 1 week since prior hematopoietic growth factor and recovered

- At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered

- Recovered from any prior therapy

Exclusion Criteria:

- Osteogenic sarcoma

- Less than 4 months

- Uncontrolled bleeding

- Congestive heart failure

- Uncontrolled hypertension

- Asthma

- Pregnant or nursing

- Uncontrolled metabolic disease

- Active severe infection

- Allergy to aminothiol compounds

- Prior bone marrow transplantation

- Other concurrent investigational agents

Study Design


Intervention

Drug:
amifostine trihydrate
Patients receive amifostine intravenous (IV) over 5 minutes beginning 30 minutes prior to melphalan and thiotepa administration on days -5 to -1. Cohorts of 3-6 patients receive escalating doses of amifostine until the maximum tolerated dose is determined.
busulfan
Patients receive oral busulfan every 6 hours on days -8 to -6.
filgrastim
All patients receive filgrastim (G-CSF) IV for 1 week.
melphalan
melphalan intravenous (IV) over 30 minutes on days -5 and -4
thiotepa
thiotepa intravenous (IV) over 2 hours on days -3 and -2.
Procedure:
peripheral blood stem cell transplantation (PBSC)
PBSC are reinfused on day 0

Locations

Country Name City State
United States University of Minnesota Cancer Center Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Masonic Cancer Center, University of Minnesota

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2